A machine-learning analysis misclassified only 5% of adults with attention-deficit/hyperactivity disorder in a study that also included adults with obesity or problematic gambling and control subjects.
AR19, an investigational stimulant for attention-deficit/hyperactivity disorder (ADHD), improved symptoms in adults with ADHD in a Phase 3 trial, according to a poster presented at Psych Congress 2020.
The US Food and Drug Administration has accepted the filing of a New Drug Application for an investigational amphetamine for the treatment of attention-deficit/hyperactivity disorder specifically designed to resist manipulation.
A meta-analysis recently published in The Lancet Psychiatry found that using medicinal cannabinoids to treat mental health disorders cannot be justified, due to a lack of evidence of effectiveness and known risks of the substances.
The American Academy of Pediatrics (AAP) has updated its 2011 clinical practice guideline on the evaluation, diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD) in children from age four to 18 years old.